Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.
BACKGROUND
The effects of pan-peroxisome proliferator-activated receptor (PPAR) ligand bezafibrate on N-terminal pro-B type natriuretic peptide (ProBNP) level in patients with coronary artery disease (CAD) is unknown. The current study aimed to investigate the long-term effects of bezafibrate on ProBNP level in patients with pre-existing CAD and advanced functional capacity impairment.


METHODS
Metabolic and inflammatory parameters were analyzed from stored frozen serum samples obtained from 108 patients enrolled in the Bezafibrate Infarction Prevention (BIP) Study. They presented with New York Heart Association (NYHA) functional class III, comprising 58 patients in the bezafibrate group and 50 in the placebo groups, and completed a 2-year prospective, double-blind, placebo-controlled follow-up.


RESULTS
During follow-up ProBNP level did not change significantly in the placebo group, whereas it increased slightly in the bezafibrate group, which was older and with lower baseline ProBNP values. No significant differences between the groups were found for ProBNP levels after 2 year of follow-up. Analysis-of-covariance (ANCOVA) -taking into account age and baseline ProBNP level- showed that bezafibrate was not associated with longitudinal ProBNP changes during the follow-up period (p = 0.3).


CONCLUSIONS
Long-term treatment by bezafibrate was not associated with longitudinal ProBNP changes in patients with pre-existing CAD and advanced functional capacity impairment.
Node
Koichi
K
Department of Cardiovascular and Renal Medicine, Saga University Faculty of Medicine, Saga, Japan. node@cc.saga-u.ac.jp
Inoue
Teruo
T
Boyko
Valentin
V
Goldberg
Ilan
I
Fisman
Enrique Z
EZ
Adler
Yehuda
Y
Schwammenthal
Ehud
E
Matas
Zipora
Z
Behar
Solomon
S
Tenenbaum
Alexander
A
D000368:Aged; D001629:Bezafibrate / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood* / Q000209:etiology; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D047495:PPAR gamma / Q000819:agonists / Q000502:physiology; D010446:Peptide Fragments / Q000097:blood*; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012720:Severity of Illness Index
D000960:Hypolipidemic Agents; D047495:PPAR gamma; D010446:Peptide Fragments; D047492:Peroxisome Proliferator-Activated Receptors; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D001629:Bezafibrate